GSH-resistant and highly cytoselective ruthenium(II)- p -cymene-(imidazo[4,5- f ][1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents

• Published in: Dalton transactions : an international journal of inorganic chemistry Vol. 50; no. 30; p. 10369
• Main Authors: Kar, Binoy, Das, Utpal, De, Sourav, Pete, Sudhindra, Sharma S, Ajay, Roy, Nilmadhab, S K, Ashok Kumar, Panda, Debashis, Paira, Priyankar
• Format: Journal Article
• Language: English
• Published: England 04-08-2021
• Subjects: Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Caco-2 Cells; Cell Survival - drug effects; Coordination Complexes - chemical synthesis; Coordination Complexes - chemistry; Coordination Complexes - pharmacology; Cymenes - chemistry; Cymenes - pharmacology; Drug Resistance, Neoplasm - drug effects; Drug Screening Assays, Antitumor; Glutathione - chemistry; HeLa Cells; Humans; Imidazoles - chemistry; Imidazoles - pharmacology; Monoterpenes - chemistry; Monoterpenes - pharmacology; Phenanthrolines - chemistry; Phenanthrolines - pharmacology; Phenols - chemistry; Phenols - pharmacology; Ruthenium - chemistry; Ruthenium - pharmacology
• ISSN: 1477-9234
• DOI: 10.1039/d1dt01604k

To avoid the side effects of the current popular platinum-based anticancer drugs, researchers have made tireless attempts to design appropriate GSH-resistant Ru(ii)-arene complexes. In this regard, luminescent ruthenium(ii)-p-cymene-imidazophenanthroline complexes were developed as promising highly cytoselective cancer theraputic agents for HeLa and Caco-2 cells.